Complete response to talazoparib in patient with pancreatic adenocarcinoma harboring somatic PALB2 mutation: A case report and literature review

被引:1
|
作者
Kachmazov, Andrei [1 ]
Bolotina, Larisa [1 ]
Kornietskaya, Anna [1 ]
Kuznetsova, Olesya [2 ,3 ]
Ivanov, Maxim [3 ]
Fedenko, Alexander [1 ]
机构
[1] Minist Hlth Russian Federat, P Hertsen Moscow Oncol Clin Res Inst, Branch Natl Med Res Radiol Ctr, Moscow, Russia
[2] NN Blokhin Natl Med Res Ctr Oncol Minist Hlth Russ, Fed State Budgetary Inst, Moscow, Russia
[3] Atlas Oncodiagnost LLC, RnD Dept, Moscow, Russia
来源
FRONTIERS IN ONCOLOGY | 2022年 / 12卷
关键词
pancreatic cancer; PDAC; talazoparib; PARP inhibitors; PARPi; PALB2; molecular profiling; precision oncology; CANCER; GEMCITABINE; TRIAL;
D O I
10.3389/fonc.2022.953908
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
PARP inhibitors have recently emerged as a maintenance treatment option for metastatic pancreatic cancer patients with germline BRCA mutations. However, the possibility of PARP-inhibitor use as a standalone-targeted therapy for patients with various homologous repair pathway alterations remains mostly undetermined. Here we report a clinical case of a 56-year-old woman with pancreatic ductal adenocarcinoma harboring a somatic PALB2 mutation. Following disease progression after 10 cycles of FOLFIRINOX chemotherapy and two cycles of second-line gemcitabine, she was switched to talazoparib and achieved a complete clinical response after 25 months of treatment. The patient remains alive without clinical or radiological signs of disease progression three years after the start of talazoparib with no targeted therapy-related toxicities. This case highlights the role of broad molecular profiling as a window of opportunity to achieve a durable response for selected pancreatic cancer patients while pinpointing our gaps in understanding the whole picture of management of these patients since a new puzzle element represented by PARP inhibitors was introduced to clinical practice.
引用
收藏
页数:6
相关论文
共 50 条
  • [31] Efficacy of osimertinib in a metastatic lung adenocarcinoma patient harboring somatic EGFR delL747_S752 and germline BIM deletion polymorphism: a case report and literature review
    Zheng, Wenyu
    Niu, Niu
    Zeng, Jialong
    Ke, Xianni
    Jin, Shi
    TRANSLATIONAL CANCER RESEARCH, 2022, : 3895 - 3902
  • [32] Lung adenocarcinoma in a patient with Lynch syndrome: a case report and literature review
    Hodges, Alan
    Sun, Kai
    Sheu, Tiffany G.
    Bernicker, Eric H.
    FRONTIERS IN ONCOLOGY, 2023, 13
  • [33] Synchronous Pancreatic Ductal Adenocarcinoma in the Head and Tail, a Double Trouble: A Case Report and Literature Review
    Paramythiotis, Daniel
    Fotiadou, Georgia
    Karlafti, Eleni
    Deka, Ioanna Abba
    Petrakis, Georgios
    Psoma, Elisavet
    Mavropoulou, Xanthippi
    Kyriakidis, Filippos
    Netta, Smaro
    Apostolidis, Stylianos
    DIAGNOSTICS, 2022, 12 (11)
  • [34] Rapid response to monotherapy with MEK inhibitor trametinib for a lung adenocarcinoma patient harboring primary SDN1-BRAF fusion: A case report and literature review
    Yu, Yang
    Yu, Min
    Li, Yanying
    Zhou, Xiaojuan
    Tian, Tian
    Du, Yijia
    Tu, Zegui
    Huang, Meijuan
    FRONTIERS IN ONCOLOGY, 2022, 12
  • [35] A Novel EGFR Germline Mutation in Lung Adenocarcinoma: Case Report and Literature Review
    Sharma, Parth
    Mahadevia, Himil
    Donepudi, Sreekanth
    Kujtan, Lara
    Gustafson, Beth
    Ponvilawan, Ben
    Al-Obaidi, Ammar
    Subramanian, Janakiraman
    Bansal, Dhruv
    CLINICAL LUNG CANCER, 2024, 25 (05) : 479 - 482
  • [36] Pancreatic adenocarcinoma metastasis to the oral cavity: A rare case report and literature review
    Moreira, C.
    Corrales, T.
    ORAL ONCOLOGY, 2021, 116
  • [37] Tumor-mutation burden as a marker for immunotherapy of pancreatic cancer: the case report and literature review
    Zhu, Peng-Fei
    Chen, Yun-Wang
    Wang, Ming-Xing
    Deng, Ya-Ya
    Pan, Shuang-Yue
    Chen, Zhe-Ling
    Yang, Liu
    ANTI-CANCER DRUGS, 2022, 33 (01) : E822 - E827
  • [38] Pancreatic Adenocarcinoma Metastasizing to the Maxillary Gingiva: Report of a Rare Case and Literature Review
    Takaoka, Shohei
    Nemoto, Masako
    Iijima, Tatsuo
    Yamagata, Kenji
    Bukawa, Hiroki
    Yanagawa, Toru
    JOURNAL OF MAXILLOFACIAL & ORAL SURGERY, 2024,
  • [39] The First Case Report of a Patient With Oligodendroglioma Harboring CHEK2 Germline Mutation
    Li, Xueen
    Xue, Hao
    Luo, Ningning
    Han, Tiantian
    Li, Mengmeng
    Jia, Deze
    FRONTIERS IN GENETICS, 2022, 13
  • [40] A case of lung adenocarcinoma with a concurrent EGFR mutation and ALK rearrangement: A case report and literature review
    Xu, Chun-Wei
    Cai, Xue-Ying
    Shao, Yuan
    Li, Yang
    Shi, Ming-Wei
    Zhang, Li-Ying
    Wang, Lin
    Zhang, Yu-Ping
    Wang, Lu-Ping
    Tian, Yu-Wang
    MOLECULAR MEDICINE REPORTS, 2015, 12 (03) : 4370 - 4375